AstraZeneca and Ionis close agreement to develop and commercialise eplontersen

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX.

The companies will jointly develop and commercialise eplontersen in the US, while AstraZeneca will develop and commercialise it in the rest of the world, except in Latin America.

from Breaking World Pharma News https://ift.tt/3HsJpOp